1. Decline in deaths from heart disease and stroke-United States, 1900~1999. MMWR Morb Mortal Wkly Rep 1999;48:649-656.
2. Ford ES, Ajani UA, Croft JB, Critchley JA, Capewell S. Explaining the decrease in U.S. deaths from coronary disease, 1980~2000. N Engl J Med 2007;356:2388-2398.
3. Changes in mortality from heart failure-United States, 1980~1995. MMWR Morb Mortal Wkly Rep 1998;47:633-637.
4. Levy D, Kenchaiah S, Larson MG, Vasan RS. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-1402.
5. Goldberg RJ, Ciampa J, Lessard D, Meyer TE, Spencer FA. Long-term survival after heart failure: a contemporary population-based perspective. Arch Intern Med 2007;167:490-496.
6. Lee MM, Oh BH, Park HS, Han SW, Ryu KH. Multicenter Analysis of Clinical Characteristics of the Patients with Congestive Heart Failure in Korea. Korean Circ J 2003;33:533-541.
7. Swedberg K, Cleland J, Nieminen MS, Pierard L, Remme WJ. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-1140.
8. Lindenfield J, Miller GG, Shaker SF, Zolty R, Kobashigawa J. Drug therapy in the Heart transplant recipient Part I to part III. Circulation 2005;111:113-117. 2004; 110: 3734-3740, 2004; 110: 3858-3865.
9. Eisen HJ, Tuzcu EM, Dorent R, Bernhart P. for the RAD study group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 2003;349:847-858.
10. Beniaminovita A, Itescu S, Letz K, Mancini DM. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 2000;342:613-619.
11. Balfore IC, Fiore A, Graff RJ, Knutsen AP. Use of rituximab to decrease panel-reactive antibodies. J Heart Lung Transplant 2005;24:628-630.
12. Taylor DO, Edwards LB, Boucek MM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report-2007. J Heart Lung Transplant 2007;26:769-781.
13. Goldstein DJ, Oz MC, Rose EA. Implantable left ventricular assist devices. N Engl J Med 1998;339:1522-1533.
14. Stevenson LW, Kormos RL, Bourge RC, Gelijns A, Griffith BP, Wichman A. Mechanical cardiac support 2000: current applications and future trial design. June 15~16, 2000 Bethesda, Maryland. J Am Coll Cardiol 2001;37:340-370.
15. Maybaum S, Mancini D, Xydas S, Torre-Amione G. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation 2007;115:2497-2505.
16. Muller J, Wallukat G, Weng YG, Hetzer R. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation 1997;96:542-549.
17. McCarthy RE 3rd, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, Baughman KL. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000;342:690-695.
18. Seong IW, Choe SC, Jeon ES. Fulminant coxsackieviral myocarditis. N Engl J Med 2001;345:379.
19. Cooper LT Jr, Berry GJ, Shabetai R. Multicenter Giant Cell Myocarditis Study Group Investigators. Idiopathic giant-cell myocarditis-natural history and treatment. N Engl J Med 1997;336:1860-1866.
20. Park JI, Jeon ES. Mechanical Circulatory Supports in the Treatment of Fulminant Myocarditis. Korean Circ J 2005;35:563-572.
21. Rhee I, Jeon ES. Giant Cell Myocarditis Manifested as Fulminant Myocarditis. Korean Circ J 2006;36:159-161.
22. Graner M, Lommi J, Kupari M, Raisanen-Sokolowski A, Toivonen L. Multiple forms of sustained monomorphic ventricular tachycardia as common presentation in giant-cell myocarditis. Heart 2007;93:119-121.
23. Rose EA, Gelijns AC, Moskowitz AJ, Oz MC, Poirier VL. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001;345:1435-1443.
24. Catanese KA, Goldstein DJ, Williams DL, Foray AT, Illick CD, Gardocki MT, Weinberg AD, Levin HR, Rose EA, Oz MC. Outpatient left ventricular assist device support: a destination rather than a bridge. Ann Thorac Surg 1996;62:646-652. discussion 653.
25. Lietz K, Long JW, Kfoury AG, Miller LW. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 2007;116:497-505.
26. Miller LW, Pagani FD, Russell SD, John R, Farrar DJ, Frazier OH. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007;357:885-896.
27. Rhee I, Gwon HC, Choi J, Sung K, Lee YT, Kwon SU, Cho DK, Lim SH, Kim SW, Lee SH, Hong KP, Park JE. Percutaneous Cardiopulmonary Support for Emergency In-Hospital Cardiac Arrest or Cardiogenic Shock. Korean Circ J 2006;36:11-16.
28. Sung K, Lee YT, Park PW, Park KH, Jun TG, Yang JH, Ha YK. Improved survival after cardiac arrest using emergent auto-priming percutaneous cardiopulmonary support. Ann Thorac Surg 2006;82:651-656.